UTHR United Therapeutics
- 259.040
- +3.900+1.53%
United Therapeutics News
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Call Transcript
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating
United Therapeutics (UTHR) has an average outperform rating and a price target range of $218 to $400, according to analysts polled by Capital IQ. Price: 258.20, Change: +3.06, Percent Change: +1.20
United Therapeutics Is Maintained at Outperform by Oppenheimer
United Therapeutics Is Maintained at Outperform by Oppenheimer
Oppenheimer: The United Therapeutics (UTHR.US) rating was maintained, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $375.00 to $400.00.
Oppenheimer: The United Therapeutics (UTHR.US) rating was maintained, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $375.00 to $400.00.
Oppenheimer Maintains Outperform on United Therapeutics, Raises Price Target to $400
Oppenheimer analyst Hartaj Singh maintains United Therapeutics with a Outperform and raises the price target from $375 to $400.
HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:UTHR) with a Buy and maintains $300 price target.
United Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 17.58% HC Wainwright & Co. → $300 Reiterates Buy → Buy 03/07/2024 27.38% Wells Fargo $309 → $32
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight
Earnings Call Summary | United Therapeutics(UTHR.US) Q1 2024 Earnings Conference
The following is a summary of the United Therapeutics Corporation (UTHR) Q1 2024 Earnings Call Transcript:Financial Performance:United Therapeutics reported a record Q1 revenue of $678 million, a grow
United Therapeutics(UTHR.US) Officer Sells US$1.71 Million in Common Stock
$United Therapeutics(UTHR.US)$ Officer ROTHBLATT MARTINE A sold 7,200 shares of common stock on Apr 29, 30, 2024 at an average price of $236.9952 for a total value of $1.71 million.Source: Announcemen
United Therapeutics Up Over 8%, on Pace for Largest Percent Increase Since November 2022 -- Data Talk
United Therapeutics Corporation ( UTHR ) is currently at $253.83, up $19.50 or 8.32% --Would be highest close since Dec. 14, 2023, when it closed at $254.09 --On pace for largest percent increase si
United Therapeutics Corporation (UTHR) Q1 2024 Earnings Call Transcript
United Therapeutics Corporation (UTHR) Q1 2024 Earnings Call Transcript
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
On Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) reported first-quarter sales of $677.7 million, up 34% year over year, beating the consensus of $623.9 million.The company reported EPS of $
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday.Shares of Powell Industries, Inc. (NASDAQ:POWL) rose sharply during Wednesday's session after the company reported
United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell
United Therapeutics (UTHR) reported Q1 net income Wednesday of $6.17 per diluted share, up from $4.86 a year earlier. Analysts polled by Capital IQ expected $5.66. Revenue for the quarter ended March
United Therapeutics Surpasses Analyst Revenue Forecasts With Strong Q1 2024 Performance
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, Vs. Street Est of $624.2M
06:37 AM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M
United Therapeutics Q1 2024 GAAP EPS $6.17 Beats $5.56 Estimate, Sales $677.700M Beat $623.966M Estimate
United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $6.17 per share which beat the analyst consensus estimate of $5.56 by 10.97 percent. This is a 26.95 percent increase over earnings of
United Therapeutics 1Q Net $306.6M >UTHR
United Therapeutics 1Q Net $306.6M >UTHR
Press Release: United Therapeutics Corporation Reports First Quarter 2024 Financial Results
United Therapeutics Corporation Reports First Quarter 2024 Financial Results SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 01, 2024-- United Therapeutics Corporation (Nasda
Analysis
Price Target
No Data
